

Efgartigimod alfa-hyaluronidase-qvfc (Vyvgart Hytrulo)

Provider Order Form rev. 7/30/2025



PATIENT INFORMATION

Referral Status: ☐ New Referral ☐ Updated Order ☐ Order Renewal

| | | |
|--------------------------------------------------------------|-------------------------------|------------------------------------|
| Patient Name: | DOB: | Patient Phone: |
| Patient Address: | Patient Email: | |
| Allergies: | <input type="checkbox"/> NKDA | Weight (lbs/kg): Height (in/cm): |
| Sex: <input type="checkbox"/> M / <input type="checkbox"/> F | Date of Last Infusion: | Next Due Date: Preferred Location: |

DIAGNOSIS (Please provide ICD-10 code in space provided)

| | |
|---------------------------------------------------------------------------|--------------|
| Myasthenia Gravis (with positive anti-acetylcholine receptor antibodies): | |
| CIDP: | |
| Other: | Description: |

REQUIRED INFORMATION (For Myasthenia Gravis)

- ☐ Start of last Vyvgart cycle _____
- Must have updated OVN showing positive response to Vyvgart and lack of disease progression & toxicity. MG-ADL score has decreased by 2 points or more from baseline.

THERAPY ADMINISTRATION & DOSING (Choose one)

For Myasthenia Gravis:

- ☐ Administer Vyvgart Hytrulo 1008mg / 11200units subcutaneously over 30-90 seconds once per week for 4weeks
- ☐ Select for additional treatment cycles _____ (indicate number of cycles)
- ☒ Monitor patient for 30mins after each injection
- ☒ May repeat cycle no sooner than 50 days from the start of the previous treatment cycle.

For CIDP:

- ☐ Administer Vyvgart Hytrulo 1008mg / 11200units subcutaneously over 30-90 seconds once per week.
- ☒ Monitor patient for 30 mins after each injection.

LABORATORY ORDERS

- | | | |
|---------------------------------------|---------------------------------------|---------------------------------------|
| <input type="checkbox"/> CBC | <input type="checkbox"/> at each dose | <input type="checkbox"/> every: _____ |
| <input type="checkbox"/> CMP | <input type="checkbox"/> at each dose | <input type="checkbox"/> every: _____ |
| <input type="checkbox"/> CRP | <input type="checkbox"/> at each dose | <input type="checkbox"/> every: _____ |
| <input type="checkbox"/> Other: _____ | | |

PRE-MEDICATION ORDERS

- ☐ Other: _____

NURSING

- ☒ Hold infusion and notify provider for abnormal vital signs or signs/symptoms of active infection or recent live vaccine.
- ☒ Provide nursing care per Nursing Procedure, including Hypersensitivity Reaction Management Protocol and post-procedure observation

ADDITIONAL ORDERS

PROVIDER INFORMATION

| | | | |
|--------------------------|--------------------------|--------|-----------|
| Preferred Contact Name: | Preferred Contact Email: | | |
| Ordering Provider: | Provider NPI: | | |
| Referring Practice Name: | Phone: | Fax: | |
| Practice Address: | City: | State: | Zip Code: |

REQUIRED DOCUMENTATION CHECKLIST (Additional documentation required for processing and insurance approval)

Required Documentation: Patient demos, copy of front and back of primary and secondary insurance, 2 most recent OVN including treatment failures or contraindications, EMG results, MRI results

Required Labs: AChR antibody, MuSK antibodies, CRP, ESR

Provider Name (print)

Provider Signature

Date

Order valid for one year unless otherwise indicated. IV solutions/diluents may be substituted as allowed per manufacturer's instructions as necessitated by product availability.

Disclaimer: By signing this form, I authorize Novella Infusion and its affiliates to act as my designated agent in submitting prior authorizations, financial assistance applications, and other clinically required information with respect to this patient and order. This enrollment form shall serve as my signature for prior authorizations and financial assistance programs, as requested.